Part I: Targeted particles for cancer immunotherapy

Current Drug Delivery

Volumn 8, Issue 3, 2011, Pages 261-273

  Hamdy, Samar ^a   Haddadi, Azita ^b   Ghotbi, Zahra ^a   Hung, Ryan W ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cancer vaccines; Dendritic cells; Immunotherapy; Nanotechnology; Targeting

Indexed keywords

CANCER VACCINE; CD16 ANTIGEN; CD40 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHITOSAN; DNA VACCINE; GLYCOPROTEIN P 15095; HYBRID PROTEIN; LEPTIN RECEPTOR; LIPOSOME; MANNOSE; POLYETHYLENEIMINE; TOLL LIKE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; NANOTECHNOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 79953804465     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720111795256101     Document Type: Review

References (138)

1. Dunn, G. P.; Old, L. J.; Schreiber, R. D. The three Es of cancer immunoediting. Ann. Rev. Immunol., 2004, 22, 329-360.
2. Rosenberg, S. A.; Yang, J. C.; Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med., 2004, 10, 909-915.
3. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer, 2005, 5, 263-274.
4. Kaufman, H. L.; Disis, M. L. Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J. Clin. Invest, 2004, 113, 664-667.
5. Underhill, D. M.; Ozinsky, A. Phagocytosis of microbes: complexity in action. Ann. Rev. Immunol., 2002, 20, 825-852.
6. th ed.; W. H Freeman: New York, 2006.
7. Trombetta, E. S.; Mellman, I. Cell biology of antigen processing in vitro and in vivo. Ann. Rev. Immunol., 2005, 23, 975-1028.
8. Luster, A. D. The role of chemokines in linking innate and adaptive immunity. Curr. Opin. Immunol., 2002, 14, 129-135.
9. Dieu, M. C.; Vanbervliet, B.; Vicari, A.; Bridon, J. M.; Oldham, E.; Ait-Yahia, S.; Briere, F.; Zlotnik, A.; Lebecque, S.; Caux, C. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med., 1998, 188, 373-386.
10. Garinot, M.; Fievez, V.; Pourcelle, V.; Stoffelbach, F.; des Rieux, A.; Plapied, L.; Theate, I.; Freichels, H.; Jerome, C.; Marchand-Brynaert, J.; Schneider, Y. J.; Preat, V. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release, 2007, 120, 195-204.
11. Garg, S.; Oran, A.; Wajchman, J.; Sasaki, S.; Maris, C. H.; Kapp, J. A.; Jacob, J. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat. Immunol., 2003, 4, 907-912.
12. Bousso, P.; Robey, E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol., 2003, 4, 579-585.
13. Winzler, C.; Rovere, P.; Rescigno, M.; Granucci, F.; Penna, G.; Adorini, L.; Zimmermann, V. S.; Davoust, J.; Ricciardi-Castagnoli, P. Maturation stages of mouse dendritic cells in growth factordependent long-term cultures. J. Exp. Med., 1997, 185, 317-328.
14. Kalinski, P.; Hilkens, C. M.; Wierenga, E. A.; Kapsenberg, M. L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today, 1999, 20, 561-567.
15. Romani, N.; Gruner, S.; Brang, D.; Kampgen, E.; Lenz, A.; Trockenbacher, B.; Konwalinka, G.; Fritsch, P. O.; Steinman, R. M.; Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 1994, 180, 83-93.
16. Nash, J.; Pini, A. Making the connections in nerve regeneration. Nat. Med., 1996, 2, 25-26.
17. Morse, M. A.; Deng, Y.; Coleman, D.; Hull, S.; Kitrell-Fisher, E.; Nair, S.; Schlom, J.; Ryback, M. E.; Lyerly, H. K. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res., 1999, 5, 1331-1338.
18. Osman, Y.; Takahashi, M.; Zheng, Z.; Koike, T.; Toba, K.; Liu, A.; Furukawa, T.; Aoki, S.; Aizawa, Y. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcrabl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia, 1999, 13, 166-174.
19. Pinilla-Ibarz, J.; Cathcart, K.; Korontsvit, T.; Soignet, S.; Bocchia, M.; Caggiano, J.; Lai, L.; Jimenez, J.; Kolitz, J.; Scheinberg, D. A. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood, 2000, 95, 1781-1787.
20. Fields, R. C.; Shimizu, K.; Mule, J. J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. U S A, 1998, 95, 9482-9487.
21. Butts, C.; Murray, N.; Maksymiuk, A.; Goss, G.; Marshall, E.; Soulieres, D.; Cormier, Y.; Ellis, P.; Price, A.; Sawhney, R.; Davis, M.; Mansi, J.; Smith, C.; Vergidis, D.; Ellis, P.; MacNeil, M.; Palmer, M. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol., 2005, 23, 6674-6681.
22. Kugler, A.; Stuhler, G.; Walden, P.; Zoller, G.; Zobywalski, A.; Brossart, P.; Trefzer, U.; Ullrich, S.; Muller, C. A.; Becker, V.; Gross, A. J.; Hemmerlein, B.; Kanz, L.; Muller, G. A.; Ringert, R. H. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med., 2000, 6, 332-336.
23. Ogihara, T.; Iinuma, H.; Okinaga, K. Usefulness of immunomodulators for maturation of dendritic cells. Int. J. Oncol., 2004, 25, 453-459.
24. Onaitis, M.; Kalady, M. F.; Pruitt, S.; Tyler, D. S. Dendritic cell gene therapy. Surg. Oncol. Clin. N. Am., 2002, 11, 645-660.
25. Tacken, P. J.; de Vries, I. J.; Torensma, R.; Figdor, C. G. Dendriticcell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol., 2007, 7, 790-802.
26. De Vries, I. J.; Krooshoop, D. J.; Scharenborg, N. M.; Lesterhuis, W. J.; Diepstra, J. H.; Van Muijen, G. N.; Strijk, S. P.; Ruers, T. J.; Boerman, O. C.; Oyen, W. J.; Adema, G. J.; Punt, C. J.; Figdor, C. G. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res., 2003, 63, 12-17.
27. Mackensen, A.; Herbst, B.; Chen, J. L.; Kohler, G.; Noppen, C.; Herr, W.; Spagnoli, G. C.; Cerundolo, V.; Lindemann, A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer, 2000, 86, 385-392.
28. Banchereau, J.; Palucka, A. K.; Dhodapkar, M.; Burkeholder, S.; Taquet, N.; Rolland, A.; Taquet, S.; Coquery, S.; Wittkowski, K. M.; Bhardwaj, N.; Pineiro, L.; Steinman, R.; Fay, J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res., 2001, 61, 6451-6458.
29. Fong, L.; Hou, Y.; Rivas, A.; Benike, C.; Yuen, A.; Fisher, G. A.; Davis, M. M.; Engleman, E. G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U S A, 2001, 98, 8809-8814.
30. Dauer, M.; Obermaier, B.; Herten, J.; Haerle, C.; Pohl, K.; Rothenfusser, S.; Schnurr, M.; Endres, S.; Eigler, A. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol., 2003, 170, 4069-4076.
31. Kvistborg, P.; Boegh, M.; Pedersen, A. W.; Claesson, M. H.; Zocca, M. B. Fast generation of dendritic cells. Cell Immunol., 2009, 260, 56-62.
32. Dauer, M.; Schad, K.; Herten, J.; Junkmann, J.; Bauer, C.; Kiefl, R.; Endres, S.; Eigler, A. FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells. J. Immunol. Methods, 2005, 302, 145-155.
33. Radulovic, S.; Brankovic-Magic, M.; Malisic, E.; Jankovic, R.; Dobricic, J.; Plesinac-Karapandzic, V.; Maciag, P. C.; Rothman, J. Therapeutic cancer vaccines in cervical cancer: phase I study of Lovaxin-C. J. Buon, 2009, 14(Suppl 1), S165-168.
34. May, M.; Brookman-May, S.; Hoschke, B.; Gilfrich, C.; Kendel, F.; Baxmann, S.; Wittke, S.; Kiessig, S. T.; Miller, K.; Johannsen, M. Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol. Immunother., 2010, 59, 687-695.
35. Suekane, S.; Nishitani, M.; Noguchi, M.; Komohara, Y.; Kokubu, T.; Naitoh, M.; Honma, S.; Yamada, A.; Itoh, K.; Matsuoka, K.; Kanayama, H. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci., 2007, 98, 1965-1968.
36. Harrop, R.; Drury, N.; Shingler, W.; Chikoti, P.; Redchenko, I.; Carroll, M. W.; Kingsman, S. M.; Naylor, S.; Melcher, A.; Nicholls, J.; Wassan, H.; Habib, N.; Anthoney, A. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res., 2007, 13, 4487-4494.
37. Kruit, W. H.; van Ojik, H. H.; Brichard, V. G.; Escudier, B.; Dorval, T.; Dreno, B.; Patel, P.; van Baren, N.; Avril, M. F.; Piperno, S.; Khammari, A.; Stas, M.; Ritter, G.; Lethe, B.; Godelaine, D.; Brasseur, F.; Zhang, Y.; van der Bruggen, P.; Boon, T.; Eggermont, A. M.; Marchand, M. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J. Cancer, 2005, 117, 596-604.
38. Kazzaz, J.; Singh, M.; Ugozzoli, M.; Chesko, J.; Soenawan, E.; O'Hagan, D. T. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J. Control. Release, 2006, 110, 566-573.
39. Niidome, T.; Huang, L. Gene therapy progress and prospects: nonviral vectors. Gene. Ther., 2002, 9, 1647-1652.
40. Mottram, P. L.; Leong, D.; Crimeen-Irwin, B.; Gloster, S.; Xiang, S. D.; Meanger, J.; Ghildyal, R.; Vardaxis, N.; Plebanski, M. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm., 2007, 4, 73-84.
41. Gamvrellis, A.; Leong, D.; Hanley, J. C.; Xiang, S. D.; Mottram, P.; Plebanski, M. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol., 2004, 82, 506-516.
42. Reece, J. C.; Vardaxis, N. J.; Marshall, J. A.; Crowe, S. M.; Cameron, P. U. Uptake of HIV and latex particles by fresh and cultured dendritic cells and monocytes. Immunol. Cell Biol., 2001, 79, 255-263.
43. Reddy, S. T.; Rehor, A.; Schmoekel, H. G.; Hubbell, J. A.; Swartz, M. A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release, 2006, 112, 26-34.
44. Rice-Ficht, A. C.; Arenas-Gamboa, A. M.; Kahl-McDonagh, M. M.; Ficht, T. A. Polymeric particles in vaccine delivery. Curr. Opin. Microbiol., 2010, 13, 106-112.
45. Areschoug, T.; Gordon, S. Pattern recognition receptors and their role in innate immunity: focus on microbial protein ligands. Contrib. Microbiol., 2008, 15, 45-60.
46. Pinzon-Charry, A.; Ho, C. S.; Maxwell, T.; McGuckin, M. A.; Schmidt, C.; Furnival, C.; Pyke, C. M.; Lopez, J. A. Numerical and functional defects of blood dendritic cells in early-and late-stage breast cancer. Br. J. Cancer, 2007, 97, 1251-1259.
47. Mesa, C.; Fernandez, L. E. Challenges facing adjuvants for cancer immunotherapy. Immunol. Cell Biol., 2004, 82, 644-650.
48. Chang, Z. L. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm. Res., 2010, 59, 791-808.
49. Celis, E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res., 2007, 67, 7945-7947.
50. Pasare, C.; Medzhitov, R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science, 2003, 299, 1033-1036.
51. Fehervari, Z.; Sakaguchi, S. Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells. Int. Immunol., 2004, 16, 1769-1780.
52. Wolska, A.; Lech-Maranda, E.; Robak, T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol. Biol. Lett., 2009, 14, 248-272.
53. Yu, R. Z.; Geary, R. S.; Leeds, J. M.; Watanabe, T.; Moore, M.; Fitchett, J.; Matson, J.; Burckin, T.; Templin, M. V.; Levin, A. A. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm. Sci., 2001, 90, 182-193.
54. Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol., 2002, 20, 709-760.
55. Yang, Y.; Huang, C. T.; Huang, X.; Pardoll, D. M. Persistent Tolllike receptor signals are required for reversal of regulatory T cellmediated CD8 tolerance. Nat. Immunol., 2004, 5, 508-515.
56. Heikenwalder, M.; Polymenidou, M.; Junt, T.; Sigurdson, C.; Wagner, H.; Akira, S.; Zinkernagel, R.; Aguzzi, A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med., 2004, 10, 187-192.
57. Ismaili, J.; Rennesson, J.; Aksoy, E.; Vekemans, J.; Vincart, B.; Amraoui, Z.; Van Laethem, F.; Goldman, M.; Dubois, P. M. Monophosphoryl lipid A activates both human dendritic cells and T cells. J. Immunol., 2002, 168, 926-932.
58. Rothe, H.; O'Hara, R. M., Jr.; Martin, S.; Kolb, H. Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)2. Diabetologia, 1997, 40, 641-646.
59. Elamanchili, P.; Lutsiak, C. M.; Hamdy, S.; Diwan, M.; Samuel, J. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J. Immunother., 2007, 30, 378-395.
60. Foged, C.; Sundblad, A.; Hovgaard, L. Targeting vaccines to dendritic cells. Pharm. Res., 2002, 19, 229-238.
61. Lutsiak, M. E.; Robinson, D. R.; Coester, C.; Kwon, G. S.; Samuel, J. Analysis of poly(D, L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res., 2002, 19, 1480-1487.
62. Diwan, M.; Elamanchili, P.; Cao, M.; Samuel, J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr. Drug Deliv, 2004, 1, 405-412.
63. Kochenderfer, J. N.; Chien, C. D.; Simpson, J. L.; Gress, R. E. Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses. J. Immunol., 2006, 177, 8860-8873.
64. Jerome, V.; Graser, A.; Muller, R.; Kontermann, R. E.; Konur, A. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant. J. Immunother., 2006, 29, 294-305.
65. Wilson, K. D.; de Jong, S. D.; Tam, Y. K. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv. Drug Deliv. Rev., 2009, 61, 233-242.
66. Hamzah, J.; Altin, J. G.; Herringson, T.; Parish, C. R.; Hammerling, G. J.; O'Donoghue, H.; Ganss, R. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J. Immunol., 2009, 183, 1091-1098.
67. Wagner, H. The immunogenicity of CpG-antigen conjugates. Adv. Drug Deliv. Rev., 2009, 61, 243-247.
68. Bianco, A.; Hoebeke, J.; Godefroy, S.; Chaloin, O.; Pantarotto, D.; Briand, J. P.; Muller, S.; Prato, M.; Partidos, C. D. Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties. J. Am. Chem. Soci., 2005, 127, 58-59.
69. Intra, J.; Glasgow, J. M.; Mai, H. Q.; Salem, A. K. Pulsatile release of biomolecules from polydimethylsiloxane (PDMS) chips with hydrolytically degradable seals. J. Control. Release, 2008, 127, 280-287.
70. Krishnamachari, Y.; Salem, A. K. Innovative strategies for codelivering antigens and CpG oligonucleotides. Adv. Drug Deliv. Rev., 2009, 61, 205-217.
71. Hamdy, S.; Elamanchili, P.; Alshamsan, A.; Molavi, O.; Satou, T.; Samuel, J. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D, L-lactic-co-glycolic acid) nanoparticles. J. Biomed. Mater. Res. A, 2007, 81, 652-662.
72. Elamanchili, P.; Lutsiak, C. M.; Hamdy, S.; Diwan, M.; Samuel, J. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J. Immunother., 2007, 30, 378-395.
73. Blander, J. M.; Medzhitov, R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature, 2006, 440, 808-812.
74. Schlosser, E.; Mueller, M.; Fischer, S.; Basta, S.; Busch, D. H.; Gander, B.; Groettrup, M. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine, 2008, 26, 1626-1637.
75. Samuel, J.; Budzynski, W. A.; Reddish, M. A.; Ding, L.; Zimmermann, G. L.; Krantz, M. J.; Koganty, R. R.; Longenecker, B. M. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int. J. Cancer, 1998, 75, 295-302.
76. Gallorini, S.; Berti, F.; Mancuso, G.; Cozzi, R.; Tortoli, M.; Volpini, G.; Telford, J. L.; Beninati, C.; Maione, D.; Wack, A. Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides. Proc. Natl. Acad. Sci. U S A, 2009, 106, 17481-17486.
77. Heuking, S.; Adam-Malpel, S.; Sublet, E.; Iannitelli, A.; Stefano, A.; Borchard, G. Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. J. Drug Target, 2009, 17, 662-670.
78. Khan, S.; Bijker, M. S.; Weterings, J. J.; Tanke, H. J.; Adema, G. J.; van Hall, T.; Drijfhout, J. W.; Melief, C. J.; Overkleeft, H. S.; van der Marel, G. A.; Filippov, D. V.; van der Burg, S. H.; Ossendorp, F. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem., 2007, 282, 21145-21159.
79. Chabot, S. M.; Chernin, T. S.; Shawi, M.; Wagner, J.; Farrant, S.; Burt, D. S.; Cyr, S.; Neutra, M. R. TLR2 activation by proteosomes promotes uptake of particulate vaccines at mucosal surfaces. Vaccine, 2007, 25, 5348-5358.
80. Zaks, K.; Jordan, M.; Guth, A.; Sellins, K.; Kedl, R.; Izzo, A.; Bosio, C.; Dow, S. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol., 2006, 176, 7335-7345.
81. Wischke, C.; Zimmermann, J.; Wessinger, B.; Schendler, A.; Borchert, H. H.; Peters, J. H.; Nesselhut, T.; Lorenzen, D. R. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int. J. Pharm., 2009, 365, 61-68.
82. Heffernan, M. J.; Kasturi, S. P.; Yang, S. C.; Pulendran, B.; Murthy, N. The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). Biomaterials, 2009, 30, 910-918.
83. Baudner, B. C.; Ronconi, V.; Casini, D.; Tortoli, M.; Kazzaz, J.; Singh, M.; Hawkins, L. D.; Wack, A.; O'Hagan, D. T. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res., 2009, 26, 1477-1485.
84. Sangha, R.; Butts, C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin. Cancer Res., 2007, 13, s4652-4654.
85. Hamdy, S.; Molavi, O.; Ma, Z.; Haddadi, A.; Alshamsan, A.; Gobti, Z.; Elhasi, S.; Samuel, J.; Lavasanifar, A. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine, 2008, 26, 5046-5057.
86. Johnston, D.; Zaidi, B.; Bystryn, J. C. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol. Immunother., 2007, 56, 1133-1141.
87. Fischer, S.; Schlosser, E.; Mueller, M.; Csaba, N.; Merkle, H. P.; Groettrup, M.; Gander, B. Concomitant delivery of a CTLrestricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J. Drug Target, 2009, 17, 652-661.
88. San Roman, B.; Irache, J. M.; Gomez, S.; Tsapis, N.; Gamazo, C.; Espuelas, M. S. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur. J. Pharm. Biopharm., 2008, 70, 98-108.
89. Kaiser-Schulz, G.; Heit, A.; Quintanilla-Martinez, L.; Hammerschmidt, F.; Hess, S.; Jennen, L.; Rezaei, H.; Wagner, H.; Schatzl, H. M. Polylactide-coglycolide microspheres coencapsulating recombinant tandem prion protein with CpGoligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses. J. Immunol., 2007, 179, 2797-2807.
90. Martinez Gomez, J. M.; Fischer, S.; Csaba, N.; Kundig, T. M.; Merkle, H. P.; Gander, B.; Johansen, P. A protective allergy vaccine based on CpG-and protamine-containing PLGA microparticles. Pharm. Res., 2007, 24, 1927-1935.
91. Beaudette, T. T.; Bachelder, E. M.; Cohen, J. A.; Obermeyer, A. C.; Broaders, K. E.; Frechet, J. M.; Kang, E. S.; Mende, I.; Tseng, W. W.; Davidson, M. G.; Engleman, E. G. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in aciddegradable microparticle vaccines. Mol. Pharm., 2009, 6, 1160-1169.
92. Chikh, G.; de Jong, S. D.; Sekirov, L.; Raney, S. G.; Kazem, M.; Wilson, K. D.; Cullis, P. R.; Dutz, J. P.; Tam, Y. K. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int. Immunol., 2009, 21, 757-767.
93. Borges, O.; Cordeiro-da-Silva, A.; Tavares, J.; Santarem, N.; de Sousa, A.; Borchard, G.; Junginger, H. E. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur. J. Pharm. Biopharm., 2008, 69, 405-416.
94. Y. Krishnamachari, M. E. P., A. K. Salem Self-Assembly of Cell-Microparticle Hybrids. Adv. mater., 2008, 20, 989-993.
95. Kerrigan, A. M.; Brown, G. D. C-type lectins and phagocytosis. Immunobiology, 2009, 214, 562-75.
96. Figdor, C. G.; van Kooyk, Y.; Adema, G. J. C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev., 2002, 2, 77-84.
97. McGreal, E. P.; Miller, J. L.; Gordon, S. Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr. Opin. Immunol., 2005, 17, 18-24.
98. Lisziewicz, J.; Trocio, J.; Whitman, L.; Varga, G.; Xu, J.; Bakare, N.; Erbacher, P.; Fox, C.; Woodward, R.; Markham, P.; Arya, S.; Behr, J. P.; Lori, F. DermaVir: a novel topical vaccine for HIV/AIDS. J. Invest Dermatol., 2005, 124, 160-169.
99. Jiang, H. L.; Kang, M. L.; Quan, J. S.; Kang, S. G.; Akaike, T.; Yoo, H. S.; Cho, C. S. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomat., 2008, 29, 1931-1939.
100. Kim, T. H.; Nah, J. W.; Cho, M. H.; Park, T. G.; Cho, C. S. Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles. J. Nanosci. Nanotechnol., 2006, 6, 2796-2803.
101. Kim, T. H.; Jin, H.; Kim, H. W.; Cho, M. H.; Cho, C. S. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol. Cancer Ther., 2006, 5, 1723-1732.
102. Liang, W. W.; Shi, X.; Deshpande, D.; Malanga, C. J.; Rojanasakul, Y. Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim. Biophys. Acta, 1996, 1279, 227-234.
103. Cui, Z.; Hsu, C. H.; Mumper, R. J. Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev. Ind. Pharm., 2003, 29, 689-700.
104. Park, K. H.; Sung, W. J.; Kim, S.; Kim, D. H.; Akaike, T.; Chung, H. M. Specific interaction of mannosylated glycopolymers with macrophage cells mediated by mannose receptor. J. Biosci. Bioeng., 2005, 99, 285-289.
105. Yeeprae, W.; Kawakami, S.; Yamashita, F.; Hashida, M. Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages. J. Control. Release, 2006, 114, 193-201.
106. Ghotbi, Z.; Haddadi, A.; Hamdy, S.; Hung, R. W.; Samuel, J.; Lavasanifar, A. Active targeting of dendritic cells with mannandecorated PLGA nanoparticles. J. Drug Target, 2010, [Epub ahead of Print].
107. Tacken, P. J.; de Vries, I. J.; Gijzen, K.; Joosten, B.; Wu, D.; Rother, R. P.; Faas, S. J.; Punt, C. J.; Torensma, R.; Adema, G. J.; Figdor, C. G. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood, 2005, 106, 1278-1285.
108. Bonifaz, L. C.; Bonnyay, D. P.; Charalambous, A.; Darguste, D. I.; Fujii, S.; Soares, H.; Brimnes, M. K.; Moltedo, B.; Moran, T. M.; Steinman, R. M. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med., 2004, 199, 815-824.
109. Cruz, L. J.; Tacken, P. J.; Fokkink, R.; Joosten, B.; Stuart, M. C.; Albericio, F.; Torensma, R.; Figdor, C. G. Targeted PLGA nanobut not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release, 2010, 144, 118-26.
110. Grossmann, C.; Tenbusch, M.; Nchinda, G.; Temchura, V.; Nabi, G.; Stone, G. W.; Kornbluth, R. S.; Uberla, K. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands. BMC Immunol., 2009, 10, 43.
111. Diebold, S. S.; Plank, C.; Cotten, M.; Wagner, E.; Zenke, M. Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat. Cell Mol. Genet., 2002, 27, 65-74.
112. Diebold, S. S.; Kursa, M.; Wagner, E.; Cotten, M.; Zenke, M. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J. Biol. Chem., 1999, 274, 19087-19094.
113. Jiang, H. L.; Kim, Y. K.; Arote, R.; Jere, D.; Quan, J. S.; Yu, J. H.; Choi, Y. J.; Nah, J. W.; Cho, M. H.; Cho, C. S. Mannosylated chitosan-graft-polyethylenimine as a gene carrier for Raw 264.7 cell targeting. Int. J. Pharm., 2009, 375, 133-139.
114. Kaur, A.; Jain, S.; Tiwary, A. K. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta. Pharm., 2008, 58, 61-74.
115. Yoo, M. K.; Park, I. Y.; Kim, I. Y.; Park, I. K.; Kwon, J. S.; Jeong, H. J.; Jeong, Y. Y.; Cho, C. S. Superparamagnetic iron oxide nanoparticles coated with mannan for macrophage targeting. J. Nanosci. Nanotechnol., 2008, 8, 5196-5202.
116. Cui, Z.; Han, S. J.; Huang, L. Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm. Res., 2004, 21, 1018-1025.
117. Wijagkanalan, W.; Kawakami, S.; Takenaga, M.; Igarashi, R.; Yamashita, F.; Hashida, M. Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J. Control. Release, 2008, 125, 121-130.
118. Brevet, D.; Gary-Bobo, M.; Raehm, L.; Richeter, S.; Hocine, O.; Amro, K.; Loock, B.; Couleaud, P.; Frochot, C.; Morere, A.; Maillard, P.; Garcia, M.; Durand, J. O. Mannose-targeted mesoporous silica nanoparticles for photodynamic therapy. Chem. Commun. (Camb), 2009, 1475-1477.
119. Zheng, X.; Vladau, C.; Zhang, X.; Suzuki, M.; Ichim, T. E.; Zhang, Z. X.; Li, M.; Carrier, E.; Garcia, B.; Jevnikar, A. M.; Min, W. P. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood, 2009, 113, 2646-2654.
120. Nchinda, G.; Kuroiwa, J.; Oks, M.; Trumpfheller, C.; Park, C. G.; Huang, Y.; Hannaman, D.; Schlesinger, S. J.; Mizenina, O.; Nussenzweig, M. C.; Uberla, K.; Steinman, R. M. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest., 2008, 118, 1427-1436.
121. Singh, S. K.; Stephani, J.; Schaefer, M.; Kalay, H.; Garcia-Vallejo, J. J.; den Haan, J.; Saeland, E.; Sparwasser, T.; van Kooyk, Y. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol. Immunol., 2009, 47, 164-174.
122. Warger, T.; Osterloh, P.; Rechtsteiner, G.; Fassbender, M.; Heib, V.; Schmid, B.; Schmitt, E.; Schild, H.; Radsak, M. P. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood, 2006, 108, 544-550.
123. Gantner, B. N.; Simmons, R. M.; Canavera, S. J.; Akira, S.; Underhill, D. M. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med., 2003, 197, 1107-1117.
124. Ferwerda, G.; Meyer-Wentrup, F.; Kullberg, B. J.; Netea, M. G.; Adema, G. J. Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cell Microbiol., 2008, 10, 2058-2066.
125. Dennehy, K. M.; Ferwerda, G.; Faro-Trindade, I.; Pyz, E.; Willment, J. A.; Taylor, P. R.; Kerrigan, A.; Tsoni, S. V.; Gordon, S.; Meyer-Wentrup, F.; Adema, G. J.; Kullberg, B. J.; Schweighoffer, E.; Tybulewicz, V.; Mora-Montes, H. M.; Gow, N. A.; Williams, D. L.; Netea, M. G.; Brown, G. D. Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur. J. Immunol., 2008, 38, 500-506.
126. Wei, H.; Wang, S.; Zhang, D.; Hou, S.; Qian, W.; Li, B.; Guo, H.; Kou, G.; He, J.; Wang, H.; Guo, Y. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin. Cancer Res., 2009, 15, 4612-4621.
127. Kempf, M.; Mandal, B.; Jilek, S.; Thiele, L.; Voros, J.; Textor, M.; Merkle, H. P.; Walter, E. Improved stimulation of human dendritic cells by receptor engagement with surface-modified microparticles. J. Drug Target, 2003, 11, 11-18.
128. Biragyn, A.; Schiavo, R.; Olkhanud, P.; Sumitomo, K.; King, A.; McCain, M.; Indig, F. E.; Almanzar, G.; Baatar, D. Tumorassociated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity. J. Immunol., 2007, 179, 1381-1388.
129. Haicheur, N.; Bismuth, E.; Bosset, S.; Adotevi, O.; Warnier, G.; Lacabanne, V.; Regnault, A.; Desaymard, C.; Amigorena, S.; Ricciardi-Castagnoli, P.; Goud, B.; Fridman, W. H.; Johannes, L.; Tartour, E. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class Irestricted presentation of peptides derived from exogenous antigens. J. Immunol., 2000, 165, 3301-3308.
130. Lee, R. S.; Tartour, E.; van der Bruggen, P.; Vantomme, V.; Joyeux, I.; Goud, B.; Fridman, W. H.; Johannes, L. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur. J. Immunol., 1998, 28, 2726-2737.
131. Vingert, B.; Adotevi, O.; Patin, D.; Jung, S.; Shrikant, P.; Freyburger, L.; Eppolito, C.; Sapoznikov, A.; Amessou, M.; Quintin-Colonna, F.; Fridman, W. H.; Johannes, L.; Tartour, E. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur. J. Immunol., 2006, 36, 1124-1135.
132. van Broekhoven, C. L.; Parish, C. R.; Demangel, C.; Britton, W. J.; Altin, J. G. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res., 2004, 64, 4357-4365.
133. Castro, F. V.; Tutt, A. L.; White, A. L.; Teeling, J. L.; James, S.; French, R. R.; Glennie, M. J. CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur. J. Immunol., 2008, 38, 2263-2273.
134. Korokhov, N.; Noureddini, S. C.; Curiel, D. T.; Santegoets, S. J.; Scheper, R. J.; de Gruijl, T. D. A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Mol. Pharm., 2005, 2, 218-223.
135. Thacker, E. E.; Nakayama, M.; Smith, B. F.; Bird, R. C.; Muminova, Z.; Strong, T. V.; Timares, L.; Korokhov, N.; O'Neill, A. M.; de Gruijl, T. D.; Glasgow, J. N.; Tani, K.; Curiel, D. T. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine, 2009, 27, 7116-7124.
136. Wallace, P. K.; Tsang, K. Y.; Goldstein, J.; Correale, P.; Jarry, T. M.; Schlom, J.; Guyre, P. M.; Ernstoff, M. S.; Fanger, M. W. Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J. Immunol. Methods, 2001, 248, 183-194.
137. Ito, D.; Ogasawara, K.; Iwabuchi, K.; Inuyama, Y.; Onoe, K. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J. Immunol., 2000, 164, 1230-1235.
138. Dominguez, A. L.; Lustgarten, J. Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine, 2010, 28, 1383-90.